A randomised controlled pilot trial of oral 11ß-HSD1 inhibitor AZD4017 for wound healing in adults with type 2 diabetes mellitus (2021)
Attributed to:
Maximising patient benefit: Leeds’ Interdisciplinary approach to translation
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2021.03.23.21254200
Publication URI: http://dx.doi.org/10.1101/2021.03.23.21254200
Type: Preprint